mAbs 2014-01-01

Monitoring therapeutic monoclonal antibodies in brain tumor.

Rima Ait-Belkacem, Caroline Berenguer, Claude Villard, L'Houcine Ouafik, Dominique Figarella-Branger, Alain Beck, Olivier Chinot, Daniel Lafitte

Index: MAbs 6(6) , 1385-93, (2014)

Full Text: HTML

Abstract

Bevacizumab induces normalization of abnormal blood vessels, making them less leaky. By binding to vascular endothelial growth factor, it indirectly attacks the vascular tumor mass. The optimal delivery of targeted therapies including monoclonal antibodies or anti-angiogenesis drugs to the target tissue highly depends on the blood-brain barrier permeability. It is therefore critical to investigate how drugs effectively reach the tumor. In situ investigation of drug distribution could provide a better understanding of pharmacological agent action and optimize chemotherapies for solid tumors. We developed an imaging method coupled to protein identification using matrix-assisted laser desorption/ionization mass spectrometry. This approach monitored bevacizumab distribution within the brain structures, and especially within the tumor, without any labeling.